Drug Search Results
More Filters [+]

Remifentanil

Alternative Names: remifentanil, remifentanyl, ultiva
Latest Update: 2024-04-02
Latest Update Note: Clinical Trial Update

Product Description

Remifentanil is a piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.

Mechanisms of Action: OPRM Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Hopital FOCH
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Remifentanil

Countries in Clinic: Australia, China, Italy, Japan, Netherlands, Spain, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Anesthesia Related|Other

Phase 1: Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

The TREX Trial

P3

Active, not recruiting

Other

2025-02-03

TREX

P3

Active, not recruiting

Anesthesia Related

2023-04-21

CNS7056-025

P1

Completed

Other

2022-01-28

21%

REMICrush

P3

Completed

Unknown

2021-04-22

Recent News Events